Lonza’s Post

Developing oligonucleotide therapeutics? On the 21st May, I will be presenting a live webinar showcasing Patsnap's groundbreaking chemical modification search tool. Identifying modifications in sequences has previously been a laborious and incredibly time consuming task, but thanks to our comprehensive modification ontologies, and AI extraction model, these pains are a thing of the past. Come along to find out how we can revolutionise your oligonucleotide development. #RNA #oligonucleotide #innovation #chemicalmodification

Great to see the growth across the industry in not just the big players, but also providers excelling in specialised areas. With a new wave of collaborations and mergers rising, how we can collectively leverage this momentum to expedite next-generation therapies?  #CDMOGrowth #PharmaceuticalInnovation #StrategicPartnerships

FastFacts now available! Addressing #purification challenges: biological pipeline diversity and smaller manufacturing scales A rapid growth in novel therapeutics has been seen in the biological pipeline in terms of new modalities entering the market in line with the increasing revenue of biologics. #mRNA is showing potential in a wide array of therapeutic modalities, including oncology, infectious disease vaccines, gene editing, cell therapy, and encoding #antibodies. In this FastFacts, Cytiva’s Dr Sushma Nayak Teichert describes the purification needs and challenges for today’s diverse biological pipeline. Watch the video or view the poster to learn about: • The growth of the novel therapeutics landscape • The therapeutic promise of mRNA • How to build flexibility into manufacturing • Small-scale #chromatography systems Watch the video or view the poster below:

The launch edition of Nucleic Acid Insights is out now. Read the interview with John Lewis describing the delivery of nucleic acids with Entos' Fusogenix PLV delivery technology. #nucleicaciddelivery #Fusogenix #PLV #Precisionmedicine

Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A Orchard Therapeutics (NASDAQ: ORTX) experienced a remarkable 97% surge in its shares following a major announcement on October 5th, 2023. The renowned global gene therapy leader, Orchard, has been successfully acquired by Kyowa Kirin (OTC: KYKOF), solidifying its position as a fully owned subsidiary. The Agreement: The agreement outlines that Kyowa plans to buy all […] The post Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A first appeared on Micro Cap Daily. The post Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A appeared first on Micro Cap Daily.

See Daniel Some's poster, “Advances in Downstream PAT for Biologics, Vaccines and Gene Vectors,’’ during this year’s ISPPP conference. Link in the comments to learn more. #ISPPP

Join Hubert Lam at the 5th RAS-Targeted Drug Development Summit who will present new data on Affini-T Therapeutics' clinical candidates targeting #KRAS mutations. Highlights will include: 1- How Affini-T Therapeutics’ TCR discovery platform has identified a library of TCRs with high functional avidity, including those targeting #KRAS G12V and G12D. 2- Understanding how through the application of #geneediting and #syntheticbiology, engineered TCR-T cells can be enhanced with improved fitness and durability to overcome the immunosuppressive tumor microenvironment. 3- #KRAS-targeted #TCR-T cell programs poised to enter clinical investigation in populations with high unmet medical needs. #KRAS #TCR #Tcell #immunotherapy #patients

Our latest webinar is now available to watch on-demand! In the webinar, we describe how flow imaging microscopy works and relates to other particle characterization methods, and how #FlowCam can support the development of safe, high-quality biotherapeutics. We review examples for protein therapeutics, #celltherapy and #genetherapy applications, followed by an engaging Q&A session. #biopharma https://hubs.li/Q02CRYls0

What does the Pharma and Biopharma #CDMO landscape look like in Europe? This infographic gives an overview of the main CDMO players in Small Molecules, Biologics and Cell & Gene therapies. With state-of-the-art facilities and 30+ years expertise in contract development and manufacturing, Merck is a major player in all these fields, supporting programs across multiple modalities and at all stages, from pre-clinical to commercial. You can download the infographic by PharmaSource here: https://lnkd.in/eZszdPfn If you are looking for a CDMO partner for your small molecule program, you can contact our experts: https://bit.ly/3zIoyrM We can accelerate your drug development and support any of the following programs: #HPAPIs, #APIs, #ADCs, Next-Generation Conjugates, Linker-Payloads, PEGs, or Targeted Protein Degradation.

SuperNuclease® is a versatile endonuclease that efficiently degrades all forms of DNA and RNA, including single-stranded, double-stranded, linear, circular, and supercoiled structures.